A Decade of SG&A: Pfizer Inc. vs. Zoetis Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry giants like Pfizer Inc. and Zoetis Inc. is crucial. Over the past decade, from 2014 to 2023, Pfizer's Selling, General, and Administrative (SG&A) expenses have shown a steady trend, averaging around $14 billion annually. In contrast, Zoetis, a leader in animal health, has maintained a more modest average of $1.7 billion, reflecting its focused market approach.

Key Insights

• Pfizer's SG&A Stability: Despite fluctuations, Pfizer's SG&A expenses remained relatively stable, with a notable dip in 2020, likely due to pandemic-related operational shifts.
• Zoetis' Growth: Zoetis saw a 31% increase in SG&A from 2014 to 2023, highlighting its strategic expansion.

These insights underscore the distinct strategies of these companies, with Pfizer's broad pharmaceutical reach and Zoetis' targeted animal health focus.